People who got the injection, retatrutide, lost 28 percent of their body weight on average after 80 weeks, Eli Lilly said.

Retatrutide, an experimental injectable drug, targets three hormones related to weight loss.

Eli Lilly’s highly anticipated new weight loss drug, retatrutide, helped people lose up to 30% of their body weight, about 85 ...

While drugs such as Wegovy target a single gut hormone, retatrutide is among a new class of GLP-1 drugs that aims at three ...

A huge international review found that GLP-1 weight-loss drugs significantly reduce the risk of heart attacks, strokes, heart ...

In a clinical trial, the new weight-loss medication retatrutide led to "clinically meaningful weight reduction," with the ...

Retatrutide helped people lose 70 pounds on average, or 28% of their body weight, in a clinical trial. The Eli Lilly weight-loss drug mimics three gut hormones.

A next-gen Eli Lilly obesity drug led to bariatric-surgery levels of weight loss in a study, but also saw patients dropping ...

A suite of new studies suggest drugs such as Ozempic and Zepbound might slow tumor progression and improve survival, but more ...

A once-weekly triple receptor agonist conferred up to 28.3% weight loss at 80 weeks for adults with overweight or obesity, ...